Bird Flu > Bird Flu News > Advaxis receives Indias DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer

Advaxis receives Indias DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will ...